Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
30 August 2017
Answer given by Mr Andriukaitis on behalf of the Commission

The Commission published EU guidelines on the prudent use of antimicrobials in human health in June 2017(1). The appropriate and prudent use of antimicrobials is essential to limiting Antimicrobial Resistance (AMR) in human and animal health.

Recognising the global dimension of AMR, the new European One Health action plan against AMR(2) has a section on the global agenda. The Commission also supports collaborative research with Sub-Saharan Africa in the context of the current European and Developing Countries Clinical Trials Partnership (EDCTP2) in particular in relation to tuberculosis, HIV/AIDS, malaria and neglected infectious diseases. To coordinate and align international AMR research activities, the Commission is supporting the Joint Programming Initiative on AMR(3) (JPIAMR). The JPIAMR is steadily expanding its membership on a global level, with India, South Africa and Egypt having recently joined.

The new European One Health action plan against AMR also proposes many actions to boost research, development and innovation on AMR. These actions aim to support research to improve knowledge on detection, effective infection control and surveillance and develop new therapeutics and alternatives, preventive vaccines and novel diagnostics.

As announced in the action plan, in order to integrate research and enhance cooperation, the Commission will facilitate sharing of antimicrobial research data among relevant stakeholders to guide future antimicrobial medicinal product discovery and development and support the establishment of a European-wide sustainable clinical research network, which should speed up clinical studies on medicinal products, lower their costs, and improve coordination of clinical research.


Last updated: 12 February 2018Legal notice